GPX4 and metabolic dysfunction-associated steatotic liver disease: Based on these mechanisms, several approaches that target the ferroptosis pathway for treating NAFLD have been explored, including sodium selenite (SS) (29), thymosin β4 (Tβ4) (31), and ENO3 (32), which modulate GPX4 to inhibit ferroptosis.